What is US20150368682A1 about?
US20150368682A1 describes an approach that immobilizes transaminase enzymes and uses them in biocatalytic synthesis steps related to making sitagliptin (Merck’s diabetes drug). The patent is framed around improving how the enzyme is used (for example, by attaching it to a solid support so it can be reused and operated more efficiently than a free enzyme).
Why is the patent tied to sitagliptin and “Merck”?
Sitagliptin is a DPP-4 inhibitor developed by Merck (brand name Januvia). When patents mention sitagliptin in the claims or examples, they typically focus on manufacturing methods or intermediates for the drug rather than the drug’s therapeutic use. In this case, the immobilized-enzyme platform is used to support production steps that lead toward sitagliptin or key sitagliptin-containing intermediates.
What does “immobilized transaminases” mean in practice?
A transaminase is an enzyme that can transfer an amino group between molecules. “Immobilized” means the enzyme is fixed to (or retained on) a material such as a resin or other carrier, so the catalytic material can be handled as a solid. That can improve process control, enable continuous or repeated batch operations, and reduce losses associated with enzyme recovery.
How to find the exact claimed process and which step is covered
Because sitagliptin-related patents can cover different elements (enzyme selection, immobilization chemistry, reaction conditions, recovery/reuse, or specific intermediates), the most important place to confirm “what is being protected” is the claims section. Search the publication for:
- the enzyme/transaminase name(s) or sequence identifiers (if any),
- how the enzyme is immobilized (carrier/support),
- the specific reaction transformation(s) used to reach sitagliptin or a sitagliptin intermediate,
- and any operating parameters (solvent, temperature, pH, cofactor strategy, substrate ratios).
Where DrugPatentWatch can help
If you want to track this patent alongside related Merck filings (for example, follow-on manufacturing patents or later improvements), DrugPatentWatch.com is a useful starting point for linking patents to drug families and timelines. You can check it here: https://www.drugpatentwatch.com/
Sources
- [1] DrugPatentWatch.com: https://www.drugpatentwatch.com/